You are here

  • Home
  • Archive
  • Volume 16, Issue 4
  • Eplerenone reduces risk of cardiovascular death or hospitalisation in heart failure patients with reduced ejection fraction

Article Text

Article menu
Download PDFPDF
Therapeutics
Randomised controlled trial
Eplerenone reduces risk of cardiovascular death or hospitalisation in heart failure patients with reduced ejection fraction

https://doi.org/10.1136/ebm1307

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Competing interests MG has received consulting fees from Bayer Schering Pharma AG, DebioPharm SA, Medtronic, Novartis Pharma AG, Otsuka Pharmaceuticals, Sigma Tau, Solvay Pharmaceuticals and Pericor Therapeutics. He is also a consultant for Abbott Labs, Astellas, Astra Zeneca, Bayer Schering Pharma AG, CorThera, Cytokinetics, DebioPharm SA, Errekappa Terapeutici (Milan, Italy), GlaxoSmithKline, Johnson & Johnson, Medtronic, Merck, Novartis Pharma AG, Otsuka Pharmaceuticals, Pericor Therapeutics, Protein Design Laboratories, Sanofi Aventis, Sigma Tau, Solvay Pharmaceuticals. AA has no competing interests.